International Symposia on Recent Advances in Otitis Media

项目总结 正在请求为三个关于中耳炎媒体最新进展的国际研讨会提供部分支持。这个 中耳炎(OM)的全球流行和引起OM的抗生素耐药细菌的惊人增加 让这成为一个严重的公共卫生问题。因此，迫切需要更好的方法来诊断、治疗 最终，预防OM。然而，要做到这一点，需要对这一点的所有方面都有完整的理解 儿科疾病，两个健康人2020年的既定目标(听力和其他感觉或交流 疾病，ENT-VSL-2：“减少儿童和青少年中耳炎”)，以及NIDCD战略计划财年 2017-2021年，其中优先领域2--了解疾病和障碍--宣布了一项改进的任务 我们对OM易感性和发病机制的认识与遗传、先天上呼吸道有关 肠道感染，咽鼓管功能障碍和反流，细菌生物被膜和微生物组，多菌制剂 感染，先天免疫失调，炎症和粘液产生，粘膜增生和 炎症的分解和组织修复的失调。确定有效的免疫途径 疫苗对中耳的保护、新治疗靶点的确定以及新技术的发展 急性和慢性OM的动物模型，疫苗接种对疾病流行率和 其他微生物的感染也被列为这一优先研究领域的主要目标。的目标 关于中耳炎最新进展的国际研讨会完全和独特地与这些 战略目标。我们坚信，科学发现的速度需要有规律、广泛和深入的 每两年回顾一次OM的研究进展。重要的是，更多的机会来定义和 为未来的研究方向和资金制定建议，每四年召开一次 研讨会内的综合研究会议(在美国召开的研讨会期间举行)也是 对我们发现和促进新的创新研究机会的集体努力具有重大价值。 因此，在得到NIDCD工作人员的许可和推荐的情况下，我们在此请求跨越 为期5年，在此期间，我们将在最近召开第20、21、22届国际研讨会 中耳炎的进展(分别为2019年、2021年和2023年)。第20次研讨会将于6月召开 9-13日在加利福尼亚州洛杉矶举行；第21届研讨会将于6月6-10日在以色列特拉维夫举行；以及 第22次研讨会将在第20次研讨会上决定的美国目的地举行。这些 研讨会预计将促进OM中不同研究学科之间更好的沟通 研究领域，并帮助弥合我们对发病机制的集体知识和理解的差距 作为OM的诊断、治疗和/或免疫学解决的可能性。本次研讨会还 一直吸引着来自许多学科和世界各地的年轻研究人员，从而确保 将继续推动该领域向前发展的下一代基础科学和临床医生研究人员。

PROJECT SUMMARY Partial support is being requested for three International Symposia on Recent Advances in Otitis Media. The worldwide prevalence of otitis media (OM) and alarming increase in antibiotic resistant bacteria that cause OM make this a serious public health problem. Thus, there is a pressing need for better ways to diagnose, treat and ultimately, prevent OM. To do so however requires a complete understanding of all aspects of this pediatric disease, a stated goal of both Healthy People 2020 (Hearing and Other Sensory or Communication Disorders, ENT-VSL-2: “Reduce otitis media in children and adolescents”), and the NIDCD strategic plan FY 2017-2021, wherein Priority Area 2 – Understanding Diseases and Disorders, declares a mandate to improve our understanding of the susceptibility and pathogenesis of OM as related to genetics, prior upper respiratory tract infection, Eustachian tube dysfunction and reflux, bacterial biofilms and microbiome, polymicrobial infections, dysregulation of innate immunity, inflammation and mucus production, mucosal hyperplasia and dysregulation of the resolution of inflammation and tissue repair. Defining the immune pathways for effective middle ear protection by vaccines and identification of new therapeutic targets as well as development of animal models of acute and chronic OM, determination of the impact of vaccination on disease prevalence and infection by other microbes are also cited as major goals within this priority research area. The objectives of the International Symposia on Recent Advances in Otitis Media are fully and uniquely aligned with these strategic goals. We strongly believe that the speed of scientific discovery requires regular broad and in-depth review of the research progress in OM every two years. Importantly, an additional opportunity to define and formulate recommendations for future research directions and funding every four years by the convening of an integrated Research Conference within the Symposium (occurs during U.S.-convened symposia) is also of great value to our collective efforts to identify and promote new and innovative research opportunities. Thereby, with permission and recommendation from NIDCD staff, herein we request support that will span a period of 5 years, during which we will convene the 20th , 21st and 22nd International Symposia on Recent Advances in Otitis Media (in 2019, 2021 and 2023, respectively). The 20th Symposium will be convened June 9-13 in Los Angeles, California; the 21st Symposium will be convened June 6-10 in Tel Aviv, Israel; and the 22nd Symposium will be convened at a U.S. destination that will be decided at the 20th Symposium. These Symposia are expected to foster improved communication amongst diverse research disciplines in the OM research field and help close gaps in our collective knowledge and understanding of the pathogenesis as well as the diagnosis, treatment and/or potential for immunological resolution of OM. This Symposium has also consistently attracted young investigators from many disciplines and from around the world, thus ensuring a future generation of both basic science and clinician investigators who will continue to move the field forward.